Valuation: Arcus Biosciences, Inc.

Market Cap 3.77B 3.3B 3.07B 2.82B 5.31B 364B 5.39B 36.53B 14.3B 178B 14.15B 13.85B 615B P/E 2026 *
-8.16x
P/E 2027 * -8.89x
Enterprise Value 3.15B 2.76B 2.56B 2.35B 4.43B 304B 4.5B 30.51B 11.94B 149B 11.82B 11.56B 513B EV / Sales 2026 *
37x
EV / Sales 2027 * 37.7x
Free-Float
70.85%
Yield 2026 *
-
Yield 2027 * -
1 day+1.66%
1 week+6.96%
Current month-2.79%
1 month+10.06%
3 months+12.58%
6 months+29.97%
Current year+25.77%
1 week 25.68
Extreme 25.68
30.02
1 month 25.68
Extreme 25.68
31.74
Current year 18.52
Extreme 18.515
31.74
1 year 8.84
Extreme 8.84
31.74
3 years 6.5
Extreme 6.5
31.74
5 years 6.5
Extreme 6.5
49.1
10 years 6.3
Extreme 6.3
49.1
Manager TitleAgeSince
President 68 01/05/2015
Chief Executive Officer 67 01/05/2015
Director of Finance/CFO 53 01/08/2020
Director TitleAgeSince
Chairman 67 01/12/2017
Director/Board Member 65 18/09/2017
Director/Board Member 71 01/05/2015
Date Insider Type Main position Quantity % Market Cap.
10/7/26 Sell

Founder

-20,067 0.0160%
24/6/26 Sell

Founder

-6,431 0.0051%
11/6/26 Free

Director

22,600 0.0180%
Change 5-day change 1-year change 3-year change Capi.($)
+1.66%+6.96%+227.18%+49.55% 3.77B
+0.84%-5.77%-5.01%+11.64% 46.06B
-0.14%-0.76%+378.26%+583.71% 38.91B
+0.39%+2.79%+8.23%+61.99% 35.57B
-1.54%-4.01%+5.95%-13.03% 33.13B
-0.87%-3.19%-1.27%+29.16% 26.42B
-1.28%-6.20% - - 16.61B
-0.67%-0.21%+10.55%+115.31% 15.08B
-4.93%-3.25%+6.12%+9.87% 14.08B
+0.40%-2.79%+3.58%-31.98% 12.81B
Average -0.59%-1.33%+70.40%+90.69% 24.24B
Weighted average by Cap. -0.46%-2.45%+71.26%+121.54%

Financials

2026 *2027 *
Net sales 85.06M 74.53M 69.19M 63.58M 120M 8.21B 122M 824M 323M 4.02B 319M 312M 13.87B 93.06M 81.54M 75.69M 69.56M 131M 8.98B 133M 902M 353M 4.39B 349M 342M 15.18B
Net income -456M -400M -371M -341M -643M -44.04B -652M -4.42B -1.73B -21.55B -1.71B -1.68B -74.44B -431M -377M -350M -322M -606M -41.54B -615M -4.17B -1.63B -20.33B -1.62B -1.58B -70.22B
Net Debt -621M -544M -505M -464M -875M -59.96B -888M -6.02B -2.36B -29.34B -2.33B -2.28B -101B -259M -227M -211M -194M -365M -25.03B -371M -2.51B -984M -12.25B -974M -953M -42.3B
Logo Arcus Biosciences, Inc.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Employees
601
Date Price Change Volume
22/07/26 US$29.97 +1.66% 1,035,308
21/07/26 US$29.48 +4.65% 1,084,357
20/07/26 US$28.17 +2.92% 1,127,440
17/07/26 US$27.37 +2.74% 781,581
16/07/26 US$26.64 -4.93% 1,303,353
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
29.97USD
Average target price
36.83USD
Spread / Average Target
+22.90%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RCUS Stock